GlassScriptPhysician profile
Christopher Andrew Straka
NPI 1801281399
$7,203.29
in general payments reported to CMS, 2019-2025
60 companies · $256 in 2025
The $256 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $53.94 · 2021: $615 · 2022: $1,667 · 2023: $3,528 · 2024: $1,084 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,467 · Consulting Fee: $2,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,467.49 |
| Consulting Fee | $2,400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $2,400.00 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $405.06 | 2021-2025 | Imfinzi |
| Merck Sharp & Dohme LLC | $356.21 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $316.78 | 2021-2025 | Erleada, Imbruvica, Rybrevant |
| Novartis Pharmaceuticals Corporation | $277.41 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $250.96 | 2022-2024 | Ninlaro, Alunbrig |
| Daiichi Sankyo INC. | $235.91 | 2021-2025 | Enhertu |
| Regeneron Healthcare Solutions, INC. | $232.57 | 2022-2024 | Libtayo |
| Puma Biotechnology, INC. | $175.35 | 2021-2024 | Nerlynx |
| Eisai INC. | $173.12 | 2021-2024 | |
| Pharmaessentia USA Corporation | $169.22 | 2023-2024 | Besremi |
| Bayer Healthcare Pharmaceuticals INC. | $150.87 | 2022-2024 | |
| Pfizer INC. | $140.18 | 2021-2024 | |
| Blueprint Medicines Corporation | $139.85 | 2021-2022 | |
| Seagen INC. | $93.32 | 2021-2023 | Adcetris |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Straka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.